Patterns of Care and Survival for Elderly Acute Myeloid Leukemia—Challenges and Opportunities

Abhishek A. Mangaonkar, Mrinal M Patnaik

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose of Review: Acute myeloid leukemia (AML) is a disease of the elderly, with a median age of diagnosis in the sixth decade of life. Mortality has declined over the last few years, but this impact is apparent only in the young, fit AML population. Outcomes for the elderly remain poor, with less than 20% 5-year overall survival rates. Hence, there is an unmet need to identify treatment strategies to maximize benefit in this age group. Recent Findings: Elderly AML is a difficult entity to treat due to both disease and patient-related factors. Treatment of this group has a lot of inter-physician and inter-institutional variability. Several objective criteria to assess biological age, impact of co-morbidities, and fitness have been published, which could be utilized to make management decisions. For old and unfit AML patients, a variety of novel therapeutic agents are currently being investigated. Summary: Objective analysis of biological age should include assessment of fitness, frailty, and co-morbidities in elderly AML. Future areas of research include development of an objective risk-based approach and its validation in clinical trials, development of novel therapeutic agents, and improvement in supportive care measures.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalCurrent Hematologic Malignancy Reports
DOIs
StateAccepted/In press - May 31 2017

Fingerprint

Acute Myeloid Leukemia
Survival
Morbidity
Therapeutics
Survival Rate
Age Groups
Clinical Trials
Physicians
Mortality
Research
Population

Keywords

  • Acute myeloid leukemia
  • Allogeneic stem cell transplant
  • Elderly AML
  • Outcomes
  • Patterns of care
  • Survival

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Patterns of Care and Survival for Elderly Acute Myeloid Leukemia—Challenges and Opportunities. / Mangaonkar, Abhishek A.; Patnaik, Mrinal M.

In: Current Hematologic Malignancy Reports, 31.05.2017, p. 1-10.

Research output: Contribution to journalArticle

@article{adb2c60270a94bfcb6a6bf7a21572e79,
title = "Patterns of Care and Survival for Elderly Acute Myeloid Leukemia—Challenges and Opportunities",
abstract = "Purpose of Review: Acute myeloid leukemia (AML) is a disease of the elderly, with a median age of diagnosis in the sixth decade of life. Mortality has declined over the last few years, but this impact is apparent only in the young, fit AML population. Outcomes for the elderly remain poor, with less than 20{\%} 5-year overall survival rates. Hence, there is an unmet need to identify treatment strategies to maximize benefit in this age group. Recent Findings: Elderly AML is a difficult entity to treat due to both disease and patient-related factors. Treatment of this group has a lot of inter-physician and inter-institutional variability. Several objective criteria to assess biological age, impact of co-morbidities, and fitness have been published, which could be utilized to make management decisions. For old and unfit AML patients, a variety of novel therapeutic agents are currently being investigated. Summary: Objective analysis of biological age should include assessment of fitness, frailty, and co-morbidities in elderly AML. Future areas of research include development of an objective risk-based approach and its validation in clinical trials, development of novel therapeutic agents, and improvement in supportive care measures.",
keywords = "Acute myeloid leukemia, Allogeneic stem cell transplant, Elderly AML, Outcomes, Patterns of care, Survival",
author = "Mangaonkar, {Abhishek A.} and Patnaik, {Mrinal M}",
year = "2017",
month = "5",
day = "31",
doi = "10.1007/s11899-017-0388-8",
language = "English (US)",
pages = "1--10",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",

}

TY - JOUR

T1 - Patterns of Care and Survival for Elderly Acute Myeloid Leukemia—Challenges and Opportunities

AU - Mangaonkar, Abhishek A.

AU - Patnaik, Mrinal M

PY - 2017/5/31

Y1 - 2017/5/31

N2 - Purpose of Review: Acute myeloid leukemia (AML) is a disease of the elderly, with a median age of diagnosis in the sixth decade of life. Mortality has declined over the last few years, but this impact is apparent only in the young, fit AML population. Outcomes for the elderly remain poor, with less than 20% 5-year overall survival rates. Hence, there is an unmet need to identify treatment strategies to maximize benefit in this age group. Recent Findings: Elderly AML is a difficult entity to treat due to both disease and patient-related factors. Treatment of this group has a lot of inter-physician and inter-institutional variability. Several objective criteria to assess biological age, impact of co-morbidities, and fitness have been published, which could be utilized to make management decisions. For old and unfit AML patients, a variety of novel therapeutic agents are currently being investigated. Summary: Objective analysis of biological age should include assessment of fitness, frailty, and co-morbidities in elderly AML. Future areas of research include development of an objective risk-based approach and its validation in clinical trials, development of novel therapeutic agents, and improvement in supportive care measures.

AB - Purpose of Review: Acute myeloid leukemia (AML) is a disease of the elderly, with a median age of diagnosis in the sixth decade of life. Mortality has declined over the last few years, but this impact is apparent only in the young, fit AML population. Outcomes for the elderly remain poor, with less than 20% 5-year overall survival rates. Hence, there is an unmet need to identify treatment strategies to maximize benefit in this age group. Recent Findings: Elderly AML is a difficult entity to treat due to both disease and patient-related factors. Treatment of this group has a lot of inter-physician and inter-institutional variability. Several objective criteria to assess biological age, impact of co-morbidities, and fitness have been published, which could be utilized to make management decisions. For old and unfit AML patients, a variety of novel therapeutic agents are currently being investigated. Summary: Objective analysis of biological age should include assessment of fitness, frailty, and co-morbidities in elderly AML. Future areas of research include development of an objective risk-based approach and its validation in clinical trials, development of novel therapeutic agents, and improvement in supportive care measures.

KW - Acute myeloid leukemia

KW - Allogeneic stem cell transplant

KW - Elderly AML

KW - Outcomes

KW - Patterns of care

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85020100003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020100003&partnerID=8YFLogxK

U2 - 10.1007/s11899-017-0388-8

DO - 10.1007/s11899-017-0388-8

M3 - Article

C2 - 28567524

AN - SCOPUS:85020100003

SP - 1

EP - 10

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

ER -